Erlotinib Completed Phase 2 Trials for Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00720304Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
NCT00392704Treatment of Head & Neck Cancer With Chemotherapy and Radiation
NCT00304278Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
NCT00281866Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer
NCT00942734Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma